AYLA:NSD-Ayala Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.50

Change

-0.34 (-4.97)%

Market Cap

USD 0.09B

Volume

0.06M

Avg Analyst Target

USD 17.50 (+169.23%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Ayala Pharmaceuticals Inc (AYLA) Stock Analysis:
Based on the Ayala Pharmaceuticals Inc stock forecasts from 5 analysts, the average analyst target price for Ayala Pharmaceuticals Inc is USD 17.50 over the next 12 months. Ayala Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ayala Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 8 negative signals. At the last closing, Ayala Pharmaceuticals Inc’s stock price was USD 6.50. Ayala Pharmaceuticals Inc’s stock price has changed by -0.11% over the past week, -2.53% over the past month and -53.07% over the last year.

About

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectabl ...Read More

Company Website : https://www.ayalapharma.com

Address : 4 Oppenheimer Street, Rehovot, Israel, 7670104

Employees : 34

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 28.68

Short Ratio : 1.80

52 Week Low : 6.26

Shorted Shares : 55,764

200 Day Moving Average : 10.58

Shorted Shares Previous Month : 80,228

50 Day Moving Average : 9.27

Shares Held By Insiders : 51.52%

Short Percentage : 1.05%

Shares Held by Institutions : 19.38%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

 USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

 USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

 USD59.51B 28.07 15.97
BNTX BioNTech SE

-7.57 (-4.47%)

 USD47.53B 6.15 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

 USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

 USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

 USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

 USD17.76B N/A N/A

ETFs Containing AYLA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.62% 22% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.62% 22% F 11% F
Trailing 12 Months  
Capital Gain -53.07% 49% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.07% 49% F 22% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -4.21% 30% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.21% 29% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 13.35% 98% A+ 84% B
Risk Adjusted Return -31.50% 21% F 11% F
Market Capitalization 0.09B 29% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 94% A 98% A+
Price/Book Ratio 3.45 44% F 36% F
Price / Cash Flow Ratio -3.35 37% F 63% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -91.76% 31% F 19% F
Return on Invested Capital -114.29% 15% F 6% F
Return on Assets -49.04% 13% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.80 67% D+ 59% F
Short Percent 1.05% 84% B 71% C-
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector